A biotech startup, R3 Bio, is proposing a radical alternative to animal testing: nonsentient 'organ sacks' that contain all the typical organs except a brain, rendering them unable to think or feel pain. This concept, backed by billionaire Tim Draper and LongGame Ventures, aims to replace lab animals with a more ethical and scalable solution.
The idea of 'organ sacks' is part of a broader trend to reduce reliance on animal testing, with the US Centers for Disease Control and Prevention winding down monkey research and the Trump administration phasing out animal experimentation across the federal government. As Alice Gilman, cofounder of R3 Bio, notes, the company's long-term goal is to make human versions of these 'organ sacks' that could be used as a source of tissues and organs for people who need them.
Inside the Platform
R3 Bio's approach involves creating 'organ sacks' using a combination of stem-cell technology and gene editing, with the potential to form into any cell or tissue in the body. The company is initially focusing on creating monkey 'organ sacks' for drug toxicity testing, with the goal of eventually creating human 'organ sacks' that could provide blood, tissue, and organs to people when their own bodies fail them.
According to Boyang Wang, CEO of Immortal Dragons, a Singapore-based longevity fund that's invested in R3, 'replacement is probably better than repair when it comes to treating diseases or regulating the aging process in the human body.' The concept of 'organ sacks' raises a number of ethical questions, but as Hank Greely, a bioethicist at Stanford University, notes, 'if you make a living entity without a brain at all, I think we'd be pretty comfortable with thinking it can't feel pain.'
The Regulatory Angle
The US Animal Welfare Act requires minimizing pain and distress for research animals, but it's not always possible. With over 60,000 nonhuman primates used for testing and experimentation in fiscal year 2024, the need for alternative solutions is pressing. R3 Bio's 'organ sacks' could potentially offer a more humane and efficient solution, but as Greely notes, 'the 'yuck factor' will be strong, and it's essential to get buy-in from the public.'
As the concept of 'organ sacks' continues to evolve, it's clear that the future of organ replacement will be shaped by technological advancements and ethical considerations. With the support of investors like Tim Draper, who believes that 'forward-thinking entrepreneurs' will drive progress, R3 Bio is pushing the boundaries of what's possible in the field of regenerative medicine.
